U.S., Europe Pharmas Plan To Increase Japanese Presence
This article was originally published in PharmAsia News
Executive Summary
Drug makers in the United States and Europe are shifting to Japan's pharmaceutical market for sales seen as more lucrative than their home business. Boehringer Ingelheim of Germany plans an increase in its Japanese medical representatives by as much as half by 2012 and Swiss maker Novartis plans to hire 100 in the next fiscal year. Pfizer of the United States plans to release 30 new drugs in Japan by 2012, all of the plans contributing to a forecast growth of as much as 5 percent. That is a percentage point better than the growth expected in five European nations and more than double that of the U.S. market. (Click here for more - a subscription may be required